RHHBY:OTCQX-Roche Holding Ltd ADR (Sponsored) (USD)

COMMON STOCK | Drug Manufacturers—General | OTCQX Marketplace

Last Closing

USD 40.35

Change

-1.30 (-3.12)%

Market Cap

USD 217.41B

Volume

1.78M

Analyst Target

USD 47.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing RHHBY

SPWO S&P World ETF 1.70 % 0.00 %

-0.01 (-0.07%)

USD 0.01B
DSTX ETF Series Solutions 0.00 % 0.00 %

+0.04 (+-0.07%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTCQX Marketplace)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.76% 80% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.76% 80% B- 76% C+
Trailing 12 Months  
Capital Gain 18.05% 77% C+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.05% 71% C- 82% B
Trailing 5 Years  
Capital Gain 14.42% 69% C- 71% C-
Dividend Return 10.89% 70% C- 52% F
Total Return 25.31% 72% C 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 2.80% 50% F 42% F
Dividend Return 5.77% 56% F 44% F
Total Return 2.97% 78% C+ 69% C-
Risk Return Profile  
Volatility (Standard Deviation) 13.30% 81% B- 90% A-
Risk Adjusted Return 43.36% 56% F 64% D
Market Capitalization 217.41B 94% A 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector